Kailera Therapeutics, Inc. (KLRA), a clinical-stage biotechnology company, on Friday announced the pricing of its initial public offering of 39.06 million shares of stock at $16 per share.
The offering is expected to raise gross proceeds of approximately $625 million, before underwriting discounts and expenses.
The company has granted underwriters a 30-day option to purchase up to an additional 5.86 million shares at the offering price, which could increase total proceeds if exercised.
Shares are expected to begin trading on the Nasdaq Global Select Market on April 17, 2026, under the ticker symbol "KLRA," with the offering anticipated to close on April 20, 2026, subject to customary closing conditions.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.